Last updated: February 4, 2026
Overview
Orthochromatic 10/11-28 is a combined oral contraceptive (COC) formulation marketed by Janssen Pharmaceuticals, part of Johnson & Johnson. It contains 0.10 mg norethindrone and 0.11 mg ethinyl estradiol, administered in a 28-day cycle. The product has been marketed globally for decades and benefits from established patent protections and market presence.
Market Position and Competitive Landscape
- Market Size: The global oral contraceptives market reached approximately USD 8.2 billion in 2022 and is projected to grow at a CAGR of 4.2% through 2030, driven by increasing demand for long-term contraceptive options and expanding emerging-market populations.
- Key Competitors: Other fixed-dose combination pills, such as Yaz (Bayer), Yasmin (Bayer), and generic equivalents, dominate the market.
- Patent Status: Janssen's patent on Ortho-Novum 10/11-28 expired in many markets by the early 2020s, increasing generic competition and pressuring revenues.
Fundamental Financials and Revenue Outlook
- Sales: Estimated global sales of Ortho-Novum 10/11-28 were approximately USD 120 million annually before patent expiry, with a decline expected due to generic entry.
- Pricing: Premium pricing during patent protection, decreasing with generics entering markets.
- Market Share: As of 2022, Ortho-Novum held roughly 15-20% of the US oral contraceptive market, with declining trends as generics gain share.
- Margins: Branded contraceptives historically generate gross margins of 70-80%. Decline in sales volume and increased competition are expected to compress margins toward 50-60%.
Investment Considerations
- Patent Expiry Impact: The core patent has expired in major markets, creating pressure on revenues. The shift to generics reduces profitability and market exclusivity.
- Regulatory Environment: Contraceptive drugs face regulatory scrutiny, but safety profiles of established formulations are well-documented, reducing risk.
- Market Trends: Growing acceptance of generic contraceptives, increased focus on women’s health, and expanding access in emerging markets bolster long-term volume growth prospects.
- Pipeline Opportunities: No significant pipeline extensions specific to Ortho-Novum; future growth relies on market expansion and lifecycle management strategies.
Risk Factors
- Competitive Pressure: Increased generic competition, pricing pressures, and possible loss of market share.
- Regulatory Risks: Changes in laws or reimbursement policies affecting contraceptive coverage.
- Market Saturation: Limited scope for significant revenue growth without innovation.
- Product Lifecycle Stage: Mature product with declining revenues, necessitating diversification.
Valuation Implications
Investment in Ortho-Novum 10/11-28 should include:
- Discounted Cash Flow (DCF): Given patent expiration, revenue projections currently show a declining trend. DCF models should incorporate decreasing cash flows, margin compression, and potential generic pricing.
- Comparable Analysis: Evaluate similar contraceptive products, adjusting for patent status, market share, and revenue trends.
- Risk-Adjusted Return: High sensitivity to patent loss, regulatory changes, and market share erosion.
Conclusion
Ortho-Novum 10/11-28 presents limited near-term growth potential due to patent expiration and generic competition. Its value lies in its established market position, brand recognition, and potential to serve as part of a diversified portfolio rather than as a standalone high-growth asset.
Key Takeaways
- The product's revenue has declined from peak levels due to patent expiration.
- Market growth is driven by demographic trends and increasing acceptance of oral contraceptives.
- Margins are under pressure due to generic competition.
- No major pipeline upgrades limit future growth prospects.
- Investment should focus on valuation adjustments reflecting declining cash flows and market dynamics.
FAQs
1. How does patent expiry influence the value of Ortho-Novum 10/11-28?
Patent expiry removes exclusivity, allowing generic manufacturers to produce cheaper versions, which reduces sales and margins for the original product.
2. What are the growth prospects for oral contraceptives globally?
Growth is primarily driven by demographic factors and rising acceptance in emerging markets. However, market saturation and patent expiry limit significant revenue increases.
3. Are there any notable pipeline developments related to this product?
No, there are no significant pipeline developments. Growth depends on market share and demographic expansion.
4. What role do regulatory policies play in the product's future?
Regulatory policies, including approval processes and reimbursement frameworks, influence market access but are less volatile for established formulations like Ortho-Novum.
5. How should investors assess the risk of investing in mature contraceptive products?
Assessing revenue decline, competitive landscape, patent expirations, and potential for lifecycle management strategies are crucial. Valuations should incorporate these factors through conservative cash flow estimates.
References
[1] Market data from Fortune Business Insights, "Oral Contraceptives Market Size, Share & Industry Analysis," 2023.
[2] Johnson & Johnson annual reports, 2020-2022.
[3] IQVIA, "Pharmaceutical Market Data," 2022.
